金斯瑞生物科技(01548.HK)非全资附属向日本提交骨髓瘤新药申请

AAFN2021-12-07

金斯瑞生物科技公布，其非全资附属公司「传奇生物」宣布，其合作夥伴杨森制药今天向日本厚生劳动省提交西达基奥仑赛的新药申请。西达基奥仑赛是一款在研的靶向B细胞成熟抗原嵌合抗原受体T细胞疗法，用於治疗复发或难治性多发性骨髓瘤成人患者。(na/w)~阿思达克财经新闻网址: www.aastocks.com

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

Rio999
2021-12-07
Rio999
节奏掌握得不错，高人

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2189681957?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","is_english":false,"pubTime":"2021-12-07 08:14","share_image_url":"https://static.laohu8.com/51f6b9126f36f92bbf92982596066e5a","id":"2189681957","market":"us","top_or_hot":-1,"title":"金斯瑞生物科技(01548.HK)非全资附属向日本提交骨髓瘤新药申请","media":"AAFN","content":"<div>\n<p>金斯瑞生物科技  公布，其非全资附属公司「传奇生物」宣布，其合作夥伴杨森制药今天向日本厚生劳动省提交西达基奥仑赛的新药申请。西达基奥仑赛是一款在研的靶向B细胞成熟抗原嵌合抗原受体T细胞疗法，用於治疗复发或难治性多发性骨髓瘤成人患者。(na/w)~阿思达克财经新闻网址: www.aastocks.com</p>\n\n<a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1147960&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">网页链接</a>\n\n</div>\n","source":"aastocks","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>金斯瑞生物科技(01548.HK)非全资附属向日本提交骨髓瘤新药申请</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n金斯瑞生物科技(01548.HK)非全资附属向日本提交骨髓瘤新药申请\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-07 08:14 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1147960&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0><strong>AAFN</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>金斯瑞生物科技  公布，其非全资附属公司「传奇生物」宣布，其合作夥伴杨森制药今天向日本厚生劳动省提交西达基奥仑赛的新药申请。西达基奥仑赛是一款在研的靶向B细胞成熟抗原嵌合抗原受体T细胞疗法，用於治疗复发或难治性多发性骨髓瘤成人患者。(na/w)~阿思达克财经新闻网址: www.aastocks.com</p>\n\n<a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1147960&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01548","symbol_name":"金斯瑞生物科技","start_time":0,"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1147960&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","article_id":"2189681957","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2189681957","pubTimestamp":1638836079,"columns":[],"sourceInfo":{"source_id":"aastocks","name":"阿思达克财经"},"weMediaInfo":null,"summary":"金斯瑞生物科技  公布，其非全资附属公司「传奇生物」宣布，其合作夥伴杨森制药今天向日本厚生劳动省提交西达基奥仑赛的新药申请。西达基奥仑赛是一款在研的靶向B细胞成熟抗原嵌合抗原受体T细胞疗法，用於治疗复发或难治性多发性骨髓瘤成人患者。(na/w)~阿思达克财经新闻网址: www.aastocks.com","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"01548":"金斯瑞生物科技","BK1141":"生命科学工具和服务","BK1583":"高瓴概念","BK1576":"医药外包概念"},"translate_title":"Kingsley Biotechnology (01548. HK), a non-wholly-owned subsidiary, submitted an application for new myeloma drugs to Japan","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"金斯瑞生物科技  公布，其非全资附属公司「传奇生物」宣布，其合作夥伴杨森制药今天向日本厚生劳动省提交西达基奥仑赛的新药申请。西达基奥仑赛是一款在研的靶向B细胞成熟抗原嵌合抗原受体T细胞疗法，用於治疗复发或难治性多发性骨髓瘤成人患者。(na/w)~阿思达克财经新闻网址: www.aastocks.com","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[{"id":606172942,"gmtCreate":1638848163281,"gmtModify":1638848267324,"author":{"id":"3486361727758741","authorId":"3486361727758741","name":"Rio999","avatar":"https://static.tigerbbs.com/c1e4178e32cb0fcff4b50f4dce9cc6b4","vip":1,"hat":"https://static.tigerbbs.com/64cc74234f338af2bc1439cca864443e","crmLevel":4,"crmLevelSwitch":0,"idStr":"3486361727758741","authorIdStr":"3486361727758741"},"htmlText":"节奏掌握得不错，高人","listText":"节奏掌握得不错，高人","text":"节奏掌握得不错，高人","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606172942","repostId":2189681957,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":1,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2189681957"}